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Abstract
Extracorporeal  membrane  oxygenation  (ECMO)  is  a  well-established  therapy  for
patients experiencing acute severe cardiac and/or respiratory failure. Unfortunately,
despite noteworthy improvements in patient selection, technology, and multidiscipli‐
nary team management, significant complications are still common. The most dramatic
and  potentially  severe  complications  are  neurologic.  However,  the  incidence  of
neurologic complications (i.e. embolic stroke, intracerebral hemorrhage, seizures, and
anoxic  injuries)  has  not  been  completely  defined.  Unfortunately,  brain  death  and
neurologic  injuries  are  significant  causes  of  morbidity  and  mortality  for  patients
requiring an ECMO support. Critical to the management of patients requiring ECMO
is a broader understanding of neurologic monitoring along with the clinical assess‐
ment and management of neurologic events. It is important to evaluate and potential‐
ly  intervene  early  in  the  event  of  a  neurologic  problem  to  minimize  its  clinical
significance. Hopefully, with a better understanding of the pathophysiology, diagnos‐
tic and therapeutic tools, and prevention strategies, the true incidence of neurologic
complications can be understood and minimized.
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1. Introduction
Extracorporeal  membrane  Oxygenation  (ECMO)  provides  cardiopulmonary  support  to
patients  with  acute  severe  refractory  cardiac  and respiratory  failure.  In  veno-veno (VV)
support, blood is drained from the venous system, oxygenated, cleared of carbon dioxide,
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and then pumped back into the central venous system (i.e. into the right atrium or cavoa‐
trial  junction),  is typically used for isolated pulmonary failure.  For patients with cardiac
failure or combined cardiopulmonary failure, venoarterial (VA) support is typically used.
Unlike VV support, in VA support, blood is returned back into the arterial system – often
as close to the coronary arteries and/or cerebral arterial system as possible. The specifics,
including indications, contraindications, techniques, and outcomes are discussed in other
chapters of this text. However, as we will discuss in this chapter, the nuances of arterial vs.
venous  inflow  might  potentially  affect  the  management,  complications,  and  outcomes,
particularly the risks of cerebral complications of these critically ill and high-risk patients.
Since the initial applications in 1960–70, pediatric patients, neonates, and infants with con‐
genital heart defects or respiratory distress syndrome seem to have been the main recipients
of this technique. Better equipment and an exponential increase in the body of knowledge
regarding its use have resulted in a dramatic increase in its utilization in the pediatric popu‐
lation. However, more significantly, there has been a tremendous increase in the adult
population for both cardiac and respiratory support [1]. ECMO use in adults covers the
spectrum of problems ranging from adults who survive cardiopulmonary resuscitation and
post-myocardial infarction-associated cardiogenic and septic shock. ECMO is being commonly
used for treatment of acute respiratory failure caused by a variety of problems [2–4]. The role
of ECMO during the H1N1 pandemic in 2009 is noteworthy, where the use of ECMO resulted
in a survival-to-discharge rate of >50–60%; it has been accepted worldwide as an appropriate
rescue therapy for these critically ill patients [5]. There is also a growing experience with the
use of ECMO as a bridge to heart and/or lung transplantation in highly selected patients in
whom end-organ recovery does not occur or is not expected. Conversely, in the world of acute
neurocritical care, ECMO has been thought to be of limited use due to the concomitant need
for anticoagulation. However, some case reports have successfully utilized this technique in
patients who suffered neurogenic pulmonary edema either In the setting of aneurismal
subarachnoid hemorrhage (SAH) preceding surgery or traumatic brain injury (TBI), thereby
opening the door to speculation regarding the possible future use in these patient populations
[6, 7].
Survival rates for patients undergoing ECMO varies dramatically. Results are often a function
of the initial primary pathological insult combined with associated comorbidities. As of 2012,
the Extracorporeal Life Support Organization (ELSO)—an international organization dedicat‐
ed to the study of ECMO (including the voluntary collection/reporting of clinical outcomes)
—reported survival rate of 50–60% for adult patients with respiratory failure and 39% for
cardiac failure patients [8]. However, survival rates in single-center registries have varied from
15% to 59% [4, 9, 10] with some reporting >80% 30-day survival rates [11]. As we will discuss
in this chapter, it is also becoming evident that mortality, morbidity, hospital length of stay,
patient care cost, and patient discharge to long-term care (LTAC) facilities appear to be closely
related to the development of neurological complications. This is particularly true for those
who develop intracerebral hemorrhage (ICH), or ischemic stroke (IS), both of which are
considered the most frequent complications and had been found in up to nine of 10 brain
studies at autopsy for patients who die after ECMO therapy [1, 9, 11]. The incidence of
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neurological complications per se vary in the literature and range from 10 to 50% with some
investigators speculating as many as 90% of patients treated with ECMO sustain some form
of therapy-associated neurologic injury [1, 9, 11]. This huge disparity is a consequence of the
lack of structural algorithms for the neurological evaluation of these patients. Most of the
outcome data have been obtained from retrospective reviews and are based on clinical exams,
imaging, pathology review, or a combination of several diagnostic assessments. Clinically
significant events versus imaging or pathological events with no clinical or neurological
consequence have also been poorly defined in these case series.
Figure 1. CT scan of a 24-year-old female patient with profound hypoxemia and septic shock. Neurologic evaluation
was limited by hemodynamic instability and need for pharmacologic paralysis. Once stabilized on ECMO, imaging
demonstrated a large hemispheric stroke of unknown etiology. Despite successful weaning from ECMO and recovery
of end-organ function, she remained in coma and family withdrew support.
Regarding the spectrum of neurological complications, embolic ischemic strokes, ischemic
watershed infarctions, ICH, SAH, seizures, brain death, and diffuse cerebral edema are the
most prevalent, followed by unexplained prolonged coma and hypoxic ischemic encephalop‐
athy. Delirium, severe neuropathy, hearing loss, and vocal cord paralysis are also to be
included here; some of these may not be directly related to ECMO, but these are secondary to
the need for prolonged intubation, mechanical ventilation, possible tracheostomy, and
prolonged ICU stays in these extremely ill and complex patients. Acute disseminated ence‐
phalomyelitis has also been reported, but its mechanism remains unclear [9].
Adding to the complexity in the determination of true ECMO-associated complications,
patients undergoing ECMO may develop neurological complications prior to the initiation of
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ECMO, during, or after decannulation. Patients first receive ECMO in emergent circumstances
where neurological examinations are rarely performed. Most patients are paralyzed, sedated,
and even undergoing mild to moderate hypothermia during the first 24–72 h giving limited
value to the bedside clinical examination [10]. Often critical care teams and neurologists are
left with the use of laboratory, electrophysiology, and imaging testing as the only tools for
detection of acute complications and determination of outcomes [12]. Unfortunately, some‐
times definitive imaging and clinical evaluations cannot be determined until the patient is
successfully stabilized (Figure 1) or weaned from the ECMO support (Figure 2).
Figure 2. MRI of a 43-year-old patient who sustained an acute respiratory arrest secondary to severe respiratory failure
from seasonable influenza. He was transferred immediately to an ECMO center and required 14 days of veno-veno
ECMO support. Despite successful weaning from ECMO with good end-organ function, he remained in a coma. Post-
ECMO MRI demonstrated an extensive diffusion defect consistent with severe anoxic brain injury/ischemia. Due to
these findings and concerns for a poor long-term neurolo The family decided toly withdraw support.
A basic understanding of the physiology of cerebral blood flow (CBF), metabolism, and the
management of complications, particularly in the context of long-term extracorporeal support,
will be the focus of this chapter as it is critical to understanding the relationships between
extracorporeal support and cerebral protection.
2. Principles of cerebral metabolism and blood flow
Under normal conditions, about 15–20% of cardiac output is devoted solely to the brain. This
equates to an average perfusion of 50–55 ml/100 g brain tissue/min, with the more metabol‐
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ically active areas (i.e., gray matter) receiving higher cerebral blood flow (CBF: 75 ml/100 g
brain tissue/min), whereas the white matter exhibits a much lower CBF (i.e. 45 ml/100 g brain
tissue/min) [13].
Regulation of CBF in the human brain is exceedingly complex, and although not fully under‐
stood, three main regulatory paradigms have been identified thus far, namely cerebral autore‐
gulation, flow-metabolism coupling, and neurogenic regulation. The first mechanism refers to the
ability of cerebral arterioles to maintain a constant CBF within a wide range of cerebral
perfusion pressures, while a functional hyperemia or coupling between cerebral metabolism
in a given area and a matched increase in regional CBF is a well-documented phenomenon.
Lastly, the prominent role of neurovascular units comprising extensive arborizations of
perivascular nerves, endothelial cells, and astrocytes has been increasingly recognized in
recent years [14].
Moderate decreases in CBF down to about 30 ml/100 g brain tissue/min are usually well
tolerated and do not typically lead to neuronal dysfunction. However, alterations in electro‐
physiological recordings become apparent once flow drops below 25 ml/100 g brain
tissue/min and completely disappear with CBF of ≤12–15 ml/100 g brain tissue/min [15]. The
early recognition of hypoperfused but not yet irreversibly injured brain (i.e. penumbra)
constitutes one of the main rationales for multimodal brain monitoring of patients undergoing
ECMO.
During ECMO support, a number of investigations have shown a significant decrease in
cerebral blood flow, with mean flow velocities on transcranial Doppler sonography about half
of those predicted for age and gender and a flow pattern characterized by decreased systolic
upstroke, lack of dichrotic notch, and continuous diastolic flow [16]. This consistent decrement
in CBF with near normalization following decannulation has been ascribed to metabolism-
flow coupling secondary to decreased cerebral metabolic rate (i.e. due to the use of sedative
agents), cerebral venous congestion secondary to jugular vein ligation (in pediatric and
neonatal cases), and left ventricular dysfunction, particularly in patients with venoarterial
ECMO [17].
Interestingly, patients who develop intracerebral hemorrhage as a complication of ECMO
seem to experience reactive hyperemia with resultant increases in CBF an average of 2–6 days
prior to clinical recognition of the acute neurologic injury, likely due to uncoupling of the flow-
metabolism regulatory mechanism. In such patients, recent ischemic injury and the use of
anticoagulants likely contribute to the elevated risk of cerebral hemorrhage [18].
2.1. Causes of neurological complications during ECMO
As previously mentioned, some of the neurological complications detected during ECMO may
be the consequence of the insult that led to the need for ECMO to begin with. The extent of
this pre-ECMO injury is impossible to predict prospectively in most cases. These patients are
either hypoxic or hypotensive before ECMO and represent a wide range of circumstances,
from cardiac arrest to severe respiratory failure and sepsis, thereby making it impossible to
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identify common denominators as predictors of outcome in the front end. Data suggest that
pre-ECMO lactic acidosis levels >10 mmol/L are associated with poor outcomes as well as the
presence of hyperpyrexia, hyperglycemia, and metabolic acidosis. Other potential contributors
to the overall injury to the central nervous system prior and during ECMO that may be
considered as independent predictors of poor outcome include high ventilatory pressures,
disseminated septic embolism, and air embolism.
In children, the ECMO cannulation approach represents a significant risk by altering blood
flow after ligation of the internal jugular vein and common carotid arteries. In adults with
extensive aortic atherosclerotic disease, arterial cannulation might result in retrograde
disruption of debris from the high pressure and flow and result in diffuse microvascular
embolic events. Cases of retrograde aortic (and carotid) dissection have also been discussed
as the potential causes of acute catastrophic injuries during cannulation and therapy. Other
similar procedures that require vascular access complications may includ currently reported
causes of embolic neurologic system to oxygenate, development of pump head thrombus, and
intracardiac thrombus are among the currently reported causes of embolic neurologic [18, 19].
All patients undergoing ECMO should be systemically anticoagulated. Exposure of blood to
non-biological surfaces leads to a chain of biological reactions, increased inflammatory
response, and increase in acute-phase reactants. This results in hypercoagulability and
potential thrombotic events. This may occur acutely within 24–48 h after initiation of the circuit
and can lead to ischemic complications including stroke. Embolic areas that become ischemic
are subsequently prone to associated hemorrhagic transformation and intra-cranial bleeding
complication. Similarly, these biological reactions, which can increase the bleeding risk via
thrombocytopenia, impaired platelet function, and consumption of clotting factors as well as
fibrinolysis associated with the therapeutic anticoagulation, increase dramatically the risk for
hemorrhagic complications, among which ICH is the most feared [20].
Different considerations for neurologic risk are based upon VA versus VV cannulation. This
is particularly true in neonates where VV ECMO has a significantly lower risk for neurologic
complications when comparing with VA ECMO [11]. However, the same findings have not
been consistently replicated in adult population. It is important to recognize that neurologic
complications increase the risk of a poor outcome, but such events are not inherently futile [21].
In the absence of a specific diagnosis of brain death, clinically significant neurologic events are
often used for justification to withdraw support on patients requiring ECMO. In one study of
87 patients treated with ECMO (for all indications), 65 experienced a neurologic event. Of these
66, 25 survived to discharge, 25 had support withdrawn, and 16 died. The distinction between
the 16 patients who were listed as having “died” versus the 25 who had “support withdrawn”
and presumed to have died remained unclear [11]. Given the potential implications and link
between neurologic events and clinical outcomes, without a doubt, a better understanding,
definitions, and management protocols are necessary.
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3. Specific complications
3.1. Intracranial hemorrhage (ICH)
ICH is most frequently reported in neonates due to easy detection using transcranial Doppler
(TCD), with the incidence varying between 26% and 52% and also the cerebellum being the
most common location at this age. Independent of the use of ECMO, the overall mortality from
ICH is 60–70% [2, 22, 23]. This contrasts dramatically with lower incidence reported in adult
population, with 2–19% patients developing ICH. The range in incidence varies depending on
the variability in the use of computed tomography (CT) scanning for diagnosis or postmortem
pathology data [10, 11, 20]. Conversely, the most common location in adult patients is
supratentorial [11]. The existence of proven independent risk factors for ICH is limited at this
time. While the duration of ECMO support and site of cannulation did not seem to affect the
rates of ICH in adults, a correlation has been noted between female gender, thrombocytopenia,
acute renal failure (Cr > 2.6 or the need for dialysis). Being female with thrombocytopenia
(<50.000) is the most important predictor. In the case of infants, prematurity, venous cannu‐
lation, carotid artery ligation, sepsis, and acidosis carried an increased risk [20]. In adults,
outcomes after ICH while on ECMO are felt to be catastrophic with mortality as high as 92.3%
[24], but successful outcomes are not uncommon [25] (Figure 3).
Figure 3. CT scan of a 25-year-old male patient who sustained a motor vehicle accident. He presented with hypother‐
mia and refractory hypoxemia from severe pulmonary contusions. Despite intraventricular hemorrhage, he was sup‐
ported on veno-veno ECMO for 4 days, 2 days without the use of systemic heparin. He was successfully weaned from
ECMO, extubated, and discharged to a rehabilitation facility 21 days postinjury (see text for reference).
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3.2. Stroke
Ischemic strokes are among the most common complications in patients on ECMO; however,
the true incidence is not known. Data currently available do not differentiate among the
mechanism of stroke, characteristics of the infarctions (for example, large vessel occlusions
versus microembolization) or the timing of the infarction with regard to outcomes. Events
caused by hypoperfusion that may have occurred during CPR leading to watershed infarctions
are thought to have completely different presentations, mechanisms, and outcomes as
cardioembolic events in patients with CHF, septic embolization, thrombosis caused by
hypercoagulability; however, these are lump together at the time of discussing incidence and
outcomes. It is therefore impossible to generalize the prediction of the prognosis of ischemic
strokes in patients with ECMO, which should be considered in a case-to-case bases, rather than
assuming that the presence of ischemic stroke equals poor prognosis.
Limited information exists regarding the true incidence of stroke as mentioned before. The
work by Omar HR et al. [26] is worth mentioning, wherein a retrospective review of all ECMO
patients at the Tampa General Hospital from 2004 to 2014 has been reviewed for detection of
incidence of radiologically proven ischemic stroke. Detecting a 5.8 % of incidence, however in
the report, they recognize the limitation of the study based on the lack of systematic studies
with the possibility of a falsely low incidence due to underreported events. In this report, the
presence of high lactic acid of >10 mmol/L prior to ECMO appeared related to an increased
incidence of stroke. Literature review has associated stroke with an increased morbidity of up
to 14% [11]. However, unfortunately, most of the adult studies tend to combine mortality for
both ischemic and hemorrhagic cases. No stroke correlation has been proven with the duration
of ECMO treatment; however, the association with high levels of lactic acid suggests that
systemic post-anoxic events is more common than ischemic strokes caused by cardiac embo‐
lization. While cannula embolization or air or atherothrombotic embolisms as mechanism are
far more common with venoarterial therapies in which abnormal or high pressure (and often
retrograde) flows in the arterial system might predispose to this complication. Unless air is
iatrogenically introduced into the system, post-oxygenator, the intrinsic filtering of modern
oxygenators has virtually eliminated the risk of ECMO circuit-induced embolic complication
[27]. Nevertheless, there is clearly much to learn in this specific area of neurologic complica‐
tions [21].
3.3. Seizures
Post-anoxic encephalopathy, stroke, and ICH are all associated with an increased risk for
development of seizures. Therefore, it is not surprising that ECMO patients also have an
increased risk. Fever, metabolic changes, and medications all contribute to this risk. Their
presentation may vary from post-anoxic myoclonus, focal, generalized seizures to subclinical
seizures. Any indication of abnormal motor function, especially while under heavy sedation,
or concern should prompt a formal evaluation. Unrecognized seizure activity, if left untreated,
can result in catastrophic neuronal ischemia/anoxic injury. Formal recommendations for the
systematic use of electroencephalography in this patients do not exist, thereby resulting in a
potentially under reported incidence and therefore poor understanding of the role that this
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entity plays in the overall outcome. Continuous EEG recording could assist with the detection
of not only seizure activity but also focal suppression of the background that could indirectly
herald the presence of a structural abnormality.
4. General brain edema/brain death
The presence of generalized brain edema is clinically heralded by either persistent coma or
physical examination findings suggestive of brain death. Systemic conditions resulting in
severe hypoxia or hypotension will result in a global decrease in cerebral blood flow or cerebral
oxygenation, which if sustained and above what the cerebral autoregulation or metabolic
coupling can compensate for, the result can be general brain edema neuronal cell death Many
of these patients are diagnosed with general brain edema within 3 days of cannulation for
ECMO [11]. This would suggest that is the brain insult suffered during the condition that led
to the need for ECMO what cause the injury and subsequent edema. Brain death occurred in
7–21% of the ECMO patients treated in academic centers [28–30].
In one recent series, 295 adult patients treated with ECMO, 21% of patients where given a
diagnosis of brain death [24]. Unfortunately, given the retrospective nature of this voluntary
registry data, no specific criteria were given to validate the method for making the diagnosis.
Brain death is a formal diagnosis for which there can be little margin of error in assessment.
Once these diagnostic criteria are met, the diagnosis is established, which thereby provides
both medical and legal grounds for terminating any and all care. Prolongation of therapies
after the establishment of brain death is unethical and potentially illegal with grounds for
litigation. Because many of the physiologic criteria and responses to bedside testing used for
the assessment of cerebral and brainstem function can be influenced by the physiologic benefits
of ECMO, the diagnosis of brain death while on ECMO can be challenging. In addition, while
several authors have advocated criteria for determining brain death in a patient supported by
ECMO, formal guidelines to assist in the making of such a critical, life-ending, diagnosis are
lacking. This topic will be further discussed below.
4.1. Neurological monitoring during ECMO
The role of the ongoing neurological assessment while patients are on ECMO support is of
particular importance in this patient population due to the high incidence of neurological
complications [1, 11, 31, 32]. Findings from neurological monitoring either physical exam,
laboratory, electrophysiological, or neuroimaging data have a high probability to result in a
change in care plan or goals of care that may definitely lead to change in outcomes and
potentially prevent further deterioration. There is no consensus regarding minimal recom‐
mended neurological assessment ether prior, during, or after ECMO. Nevertheless, to the
extent possible, all patients on ECMO – even when heavily sedated and pharmacologically
paralyzed – require very close and frequent neurologic assessment consistent with routine ICU
clinical monitoring. Given the high risk and incidence for adverse neurologic complications,
as discussed, any and all neurologic changes in patients undergoing ECMO therapy require
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early and aggressive evaluation and management. Limited data exist regarding the predictive
value of the different monitoring modalities and in particular physical examination prior and
during treatment on ECMO outcomes.
4.2. Physical exam
As itor response to noxious stimulation. Most of this could be continued during ECMO
support, limited only by sedation and paralysis, in which case, only pupillary studies may be
followed. The latest can be done using an automatic computerized measure to avoid examiner
variability (Figure 4). As with any critical care patient, we suggest the establishment of sedation
vacation protocols that would facilitate clinical examination whenever possible. Identification
of changes in physical exam findings has been followed traditionally by a need in cranial
imaging.
Figure 4. The NPi-200 Pupillometer (Neuroptics Inc, Irvine CA, USA, http://www.neuroptics.com) uses quantitative
infrared technology that objectively and accurately measures and trends the pupillary size and reactivity in critically ill
patients. Eliminating inaccuracies caused by interpreter reliability. Measurement of NPi, (Neurologic pupillary index),
maximal diameter at rest and maximal constriction as well as calculating % change and latency time between initiation
of stimulation and onset of constriction. MCV, (maximum constriction velocities, mm/sec) is also calculated in each
eye.
4.3. Imaging
Choices for imaging techniques are also limited during ECMO. While in infants, transcranial
Doppler (TCD) provides extraordinary bedside imaging data prior to the closure of the
fontanels; in adults, cranial computed tomography (CT) is preferred and TCD is limited to
assessment of cerebral blood flow dynamics, detection of increase in ICP, and detection of
microembolism [33]. Due to the ferrous properties of the ECMO pump and circuit, magnetic
resonance imaging while on ECMO is obviously contraindicated.
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4.4. Cranial computed tomography (CT)
Transportation of these patients outside of the ICU is not only technically and physically
difficult but also potentially dangerous [34]. For the most part, presumably, only a few patients
undergo CT during actual ECMO and most are tested after decannulation. Up to 95 % of the
complications found in infants and 85 % in pediatric and adult patients are found in the first
3–4 days on ECMO support, undelaying the need of imaging technique protocols during
ECMO [9, 18]. The availability of portable CT scans is of particular use in the ECMO centers.
With wider availability of portable CT scanning or easier transport of patient due to more
compact ECMO circuit design, the hope is that closer monitoring or more frequent imaging
might improve the overall understanding of ECMO therapies on clinical neurologic events
and outcomes. Clearly, more comprehensive, and potentially prospective data and studies,
are required in this area.
In a study by Marika K et al., 37% of patients who underwent cranial CT scanning during
ECMO were found to have either ICH, IS, or generalized brain edema. Imaging findings were
not always associated with clinical findings proving underreporting of neurological compli‐
cations based on clinical exam alone, but the results of CT had a significant impact in clinical
management, change in goals of care, and surgical indications [9, 11].
5. Electrophysiological monitoring
5.1. Somatosensory-evoked potentials (SSEPs)
Evoked potentials are electrical signals generated by the nervous system in response to sensory
stimuli. In SSEPs, an electrical stimulus is applied to the median nerve at the wrist, the common
peroneal nerve at the knee, or the posterior tibial nerve at the ankle, while electrodes are placed
along the neuraxis measure latency and amplitude. The median nerve is the most commonly
stimulated site and scalp electrodes overlying the contralateral somatosensory cortex record
the so-called N20 component of the evoked potential.
The cortical generators of the N20 component are located in the territory of the middle cerebral
artery and various studies have correlated decreased N20 amplitude (by >50%) with cerebral
hypoperfusion in this vascular distribution [35, 36]. Furthermore, the absence of SSEPs in the
setting of cardiac arrest and global cerebral ischemia strongly correlates with poor neurologic
outcome, while its presence is not sensitive enough to predict a favorable one [37].
In patients undergoing ECMO, SSEP responses can be asymmetric between right and left
hemispheres in up to 15% of cases [38]. Abnormalities (or absence) of the N20 component
following median nerve stimulation seem to have a prognostic value for poor neurologic
outcome, similar to other instances of global cerebral ischemia [39]. Future studies are
warranted to further refine its role in ECMO patients.
Neurologic Issues in Patients Receiving Extracorporeal Membrane Oxygenation Support
http://dx.doi.org/10.5772/64269
331
5.2. Electroencephalography (EEG)
In major medical centers, frequent or even continuous EEG monitoring of patients with
devastating neurologic injuries is becoming commonplace, and patients undergoing ECMO
support should not be an exception to this rule. Akin to cardiac telemetry, this form of
monitoring (“neurotelemetry”) can assist in the identification and early treatment of reversible
conditions, which could then lead to improved neurologic outcomes in this patient population.
With this in mind, EEG monitoring can serve three main purposes: early identification of
cerebral ischemia, recognition of seizure activity, and assisting with prognostication. While a
review of the complexities of EEG testing and interpretation are beyond the scope of this
chapter, an understanding of the basics – particularly as applied to ECMO patients – is
important to clinical management (Figure 5a and b).
Figure 5. (a) Initial EEG in a 40-year-old, status post cardiopulmonary arrest and initiation of ECMO therapy for acute
respiratory failure. CPR had been conducted on and off for over 60 min, at home, during transport to hospital and then
during salvage cardiac catheterization. A 16-channel digital EEG recording 1 h after arrival to the ICU demonstrating
low amplitude and severe suppression of the background rhythms with superimposed drug effect. No evidence of
asymmetry or paroxysmal discharges. (b) Follow-up EEG (approximately 1 week later). A 16-channel digital EEG re‐
cording of the same patient with clinical examination concerning persistent coma off sedation and after discontinua‐
tion of ECMO. EEG demonstrates generalized suppression, which however has improved in amplitudes. No
paroxysmal or asymmetric patterns were detected, despite concern for an asymmetric tone of limbs in the clinical ex‐
am. Patient recovered consciousness 48 h, following this EEG and was discharged 2 weeks later with no neurological
deficits.
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Following decreased CBF and ensuing cerebral ischemia, EEG changes progress from the loss
of faster frequencies (i.e. beta and alpha) to slowing, first with excess theta and, as ischemia
worsens, with excess delta waves. Finally, suppression of all frequencies usually indicates
neuronal cell death and infarction. Periodic lateralized epileptiform discharges (PLEDs),
stimulus-induced periodic rhythmic or ictal discharges (SIRPIDs), unilateral attenuations, and
asymmetric triphasic waves can all be seen in patients with cerebral ischemia and aid in early
recognition and prevention of irreversible injury [40].
The relatively high risk of both ischemic and hemorrhagic stroke during ECMO support
leading to irreversible brain injury can in turn elevate the risk of clinical as well as non-
convulsive seizures (as mentioned above). The incidence of clinical seizures during ECMO
ranges from 2 to 10%, with somewhat higher rates in younger children [41]. However, the rates
of subclinical seizures have been reported to be as high as 17%, including 11% with non-
convulsive status epilepticus [42]. Furthermore, the occurrence of seizures seems to be
associated with neurodevelopmental disorders in neonates as well as an increased risk of death
and worse functional outcomes [43]. Continuous EEG monitoring can help with early identi‐
fication of ictal patterns and guidance of pharmacologic treatment.
While more studies are still required, the presence of EEG background abnormalities and
certain electrographic patterns can aid in the prediction of neurologic outcome after ECMO
support. In one study, the presence of an unexplained burst suppression pattern was associated
with an increased risk of death or severe disability [44], while low voltage or isoelectric EEG
patterns are usually correlated with poor outcomes after global cerebral ischemia [45].
6. Laboratory studies as predictors of neuronal injury and clinical outcome
6.1. Biomarkers as predictors of neuronal injury and clinical outcome
Given that neuromonitoring modalities during ECMO vary widely among institutions and
their reported use is limited to small studies, the introduction of plasma biomarkers has
emerged as a monitoring tool to aid in outcome prediction for patients on ECMO. An ideal
biomarker would have high sensitivity for detection of both ischemic and hemorrhagic injury,
provide real-time information, and allow detection of injury at the cellular level that precedes
cellular death. While such an ideal marker is not available yet, a number of plasma proteins
have been studied to date.
In general, these biomarkers can be divided into three groups, those that reflect glial injury
(glial fibrillary acidic protein [GFAP] and S100b), those indicative of neuronal injury (neuron-
specific enolase [NSE], intercellular adhesion molecule-5 [ICAM-5], and brain-derived
neurotrophic factor [BDNF]), and those suggestive of increased neuroinflammation (ICAM-5
and monocyte chemoattractant protein 1/chemokine (C-C motif) ligand 2 [MCP-1/CCL-2]) [43].
For instance, elevated plasma levels of GFAP in patients with ECMO were associated with a
higher risk of brain injury and death (odds ratio of 11.5 and 13.6, respectively) [44]. Similarly,
S100B may serve as an early indicator of cerebral complications, in particular intracerebral
hemorrhage [46].
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In a more recent investigation, a combination of six different biomarkers measured daily for
the duration of ECMO demonstrated that GFAP, MCP-1/CCL-2, NSE, and S100b were all
significantly higher in patients with unfavorable outcomes and that peak concentrations of
GFAP, NSE, S100b, and MCP-1/CCL-2 were higher in non-survivors [47]. Even after adjusting
for potentially confounding variables, GFAP and NSE remained significantly associated with
unfavorable outcome and NSE associated with increased mortality. Lastly, elevated concen‐
trations of GFAP and ICAM-5 predicted abnormal neuroimaging in this cohort. Taken
together, while validation in larger studies is still required, these results suggest that the
biomarkers mentioned above could serve as indicators for obtaining further investigations (i.e.
neuroimaging) and for initiation of neuroprotective therapies.
7. Brain death examination
The America Academy of Neurology (AAN) has outlined criteria for the determination of brain
death [48]. Given the high reported mortality rates—and in particular, brain death—in patients
treated with ECMO, a thorough understanding of the definition and determinations of brain
death is critical. Despite the importance of the assessment of brain death, objective protocols
for patients on ECMO are clearly lacking.
A key component to the determination of brain death in the ECMO patient is the bedside
clinical exam—ideally performed by a neurologist or clinician specifically skilled, or creden‐
tialed, in the assessment of brain function in ICU patients. The first step is to evaluate for coma.
Coma is defined by the lack of all responsiveness, including eye opening or movement
(spontaneous or provoked) and motor function in response to painful stimuli (not including
spinal reflects). The potentially reversible causes of coma must be excluded (Table 1):
Acid-base abnormalities
Electrolyte abnormalities
Endocrine complications
Presence of central nervous system depressants (neuromuscular blockade, suppressive drugs/medications
Hypothermia
Hypotension
Hypovolemia
Table 1. Potentially reversible causes of coma.
Other components to the clinical exam must include assessment of brainstem reflects and
cranial nerve testing. Any evidence of brainstem function, or an incomplete assessment, is, by
definition, inconsistent with a diagnosis of brain death (Table 2).
Continuous electroencephalographic (EEG) testing can be helpful when positive, but external
electromagnetic energy sources, including the pump and ECMO circuitry, can make conclu‐
sive interpretation of results difficult. Cerebral angiography or nuclear scanning may docu‐
ment the absence of cerebral blow flow, but such testing in patients on ECMO can be difficult
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as transporting the patient and all of the mechanical equipment (ventilator, ECMO system,
etc.) to remote areas of the hospital for testing can be dangerous and sometimes logistically
impossible (i.e. will all of the equipment, the patient, and necessary clinical staff fit in a
transport elevator?).
Prerequisites
Exclude the presence of central nervous system depressant drugs, neuromuscular blocking agents.
Rule out severe electrolyte, acid-base, or endocrine disturbance
Achieve normal core temperature
Achieve normal blood pressure (systolic blood pressure >100 mmHg)
Clinical evaluation of a coma
Absence of eye opening or movement to noxious stimuli
Absence of motor response other than spinally mediated reflexes to noxious stimuli
Absence of brainstem reflexes
Absence of pupillary response to a bright light in both eyes
Absence of ocular movement using oculocephalic and oculovestibular testing
Absence of corneal testing
Absence of facial muscle movement to noxious stimuli
Absence of pharyngeal and tracheal reflexes
Apnea test absence of breathing drive to carbon dioxide challenge
Ancillary tests
Electroencephalography, cerebral angiography, nuclear scan, transcranial Doppler, cerebral tomography angiography,
and magnetic resonance imaging/angiogram
Table 2. Brain death criteria.
Formal apnea testing is the key procedure used in the establishment of brain death. The
principle behind the test is that the absence of an appropriate respiratory drive, as manifested
by an increased in PaCO2 following a CO2 challenge, is indicative of a potentially irreversible
brain-stem injury and, therefore, when positive, supportive of the diagnosis of brain death.
Specific criteria must be met prior to attempting an apnea test. In the absence of a history of
comorbidities that might predispose to abnormalities in, or blunted responses to, CO2 retention
(e.g. COPD, sleep apnea, and/or morbid obesity), such testing can be diagnostic. Proper
conduct of the test involves insuring an adequate blood pressure, preoxygenation with 100%
oxygen for at least 10 min with a goal PaO2 > 200 mmHg, normo-capnia with a ventilatory rate
of 10 breaths/min, and a reduction of positive end-expiratory pressure to ∼ 5 mmHg. If the
patient remains hemodynamically stable and blood saturation remains >95%, then a baseline,
pretest, arterial blood gas is obtained. The patient is then disconnected from the ventilator, but
given a source of oxygen. A continuous source of oxygen, such as a T-piece or cannula placed
directly into the trachea, is mandatory to prevent acute hypoxemia and therefore in validating
the test. Continuous monitoring of the patient, looking for any evidence of respiratory function,
gasping, or chest rise is required. Any signs of initiating a breath during the test should prompt
discontinuation of the test and rule out a diagnosis of “brain death”. Hypotension or desatu‐
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ration mandate test termination. After 8 min of observation, a repeat blood gas is obtained. If
the PCO2 level is >60 mmHg or 20 mmHg above the baseline, then the test is considered positive
and diagnostic of brain death. Longer periods of apnea (10–15 min), provided the patient
remains hemodynamically stable, can be used when the initial blood gas results or clinical
findings are inconclusive. Unfortunately, patients who require ECMO support often have
physiologic conditions that might further challenge apnea testing. For patients being support‐
ed on veno-arterial ECMO, pulsatile flow and blood pressures might be too low as mandated
by the AAN prior to attempting an apnea test. As discussed above, a systolic blood pressure
>100 mmHg is a prerequisite for apnea testing – a threshold that might be very difficult to
accomplish in patients on VA-ECMO with non-pulsatile flow in the absence of significant
doses of vasoactive agents. In such circumstances, some experts have advocated using mean
arterial pressure of 75-80 mmHg as an appropriate surrogate [49].
To compensate for the confounding influence of the inherent ability of the ECMO circuit to
not only provide hemodynamic stability, but more importantly, to maintain adequate
oxygenation and normal PCO2 levels, some investigators have proposed modifications of
ECMO flows and gas exchange during apnea testing. However, such experiences are limited
to a small series of patients. For example, Reddy and colleagues from the Mayo Clinic
advocating preoxygenation with 100% oxygen using the ECMO circuit. An initial blood gas is
obtained and the ECMO sweep flow was then reduced to 0.5 liters/min to minimize CO2
removal while providing some degree of continuous oxygen support. It has been advocated
that at minimal sweep levels, supplemental oxygen (i.e. given directly to the trachea or
airways) is not necessary. With an adequate flow (75–80% of cardiac output) and oxygen
through the ECMO, significant decreases in PO2 and hypoxemia should not occur [47]. Patients
were disconnected from the ventilator and after 8 min of observation (for clinical evidence of
a respiratory drive), a repeat blood gas was obtained. In two patients, a rise in PaCO2 over 60
mmHg or greater than 20 mmHg above baseline was reported, which confirmed brain death
[50]. This group of investigators also reported a series of three critically ill patients on ECMO
support, each of who experienced catastrophic neurologic complications consistent clinically
with brain death. However, in each of these patients, apnea testing could not be safely
performed due to the absence of a defined protocol and hemodynamic instability. Neverthe‐
less, they advocated the use of apnea testing using the protocol they described in their initial
patients to assist in the timely diagnosis of brain death in appropriate patients. The benefits of
a timely and definitive diagnosis include increased potential for organ donation, decreased
resource utilization in futile cases, and most importantly definitive information for the family
[51]. Such testing can be difficult because decreasing the sweep gas too much may theoretically
result in a significant hypoxemia – and mandate cessation of the test – before a significant
increase in PaCO2 can occur to yield a definitive result [52].
Because apnea testing is dependent on intrinsic brainstem response to initiate a breath in the
setting of increasing levels of carbon dioxide, it has been suggested that in patients treated
with ECMO the addition of exogenous CO2 could safely and more efficiently facilitate this
test. A significant concern for apnea testing is the ability to safely provide an oxygen source
during testing. Oxygen depravation, particularly in an already compromised and potentially
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brain injured patient, may worsen an anoxic injury. While ECMO is used to eliminate CO2
(while supplementing oxygen), in theory, ECMO can be used to increase PaCO2 levels. Pirat
and colleagues describe the addition of a CO2 source to the ECMO circuit gas blender and the
flow was initiated at 0.5 liters/min and titrated to an end titer of CO2 of 60 mmHg. The PaO2
level was then confirmed with blood gas after a period of clinical observation. They suggested
that the addition of carbon dioxide was safer by minimizing hypoxemia and hemodynamic
instability that might come with the removal of ventilatory (or gas sweep/flow) support [53].
Clearly, while such an approach sounds intriguing and physiologically possible, confirmatory
studies are necessary prior to wider use.
8. Conclusions
Without a doubt, ECMO has proven to be a valuable therapy for patients with severe acute
respiratory and/or cardiac failure. Early initiation of the therapy, prior to the development of
irreversible end-organ function, has been shown to improve outcomes in critically ill patients.
Unfortunately, despite improved technologies, earlier and more aggressive therapy and a
better understanding of the complex pathophysiology and human-extracorporeal circuit
interface, complications are still common. Neurologic complications, either as a function of
preECMO comorbidities, presenting illnesses, or as a consequence of the intricacies of either
veno-veno or veno-arterial support are unfortunately not uncommon. Such complications can
manifest in a variety of anoxic, embolic, hemorrhagic, metabolic, or functional ways and are
often a source of significant morbidity and mortality. Early and aggressive monitoring,
diagnostic testing, optimization of cerebral perfusion, and oxygenation might not prevent
complications, but might limit their impact by allowing for optimization of neuroprotective
interventions. In addition, earlier testing might also provide better prognostic implications of
therapy and allow for optimal resource utilization, including patient selection for ECMO. As
many patients experience neurologic complications, even in the absence of definitive and
comprehensive testing, a more thorough understanding of the problem will allow for better
management tools and therapies. Hopefully, this review not only illustrates the complex scope
of this problem but provides the foundation for further explorations into how to better protect
the brain while on extracorporeal membrane oxygenation support.
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